Eric Schettini (TAFALGIE THERAPEUTICS)
Overview
Eric Schettini is a prominent entrepreneur and investor known for his significant contributions to the biopharmaceutical sector. He is the founder and CEO of Tafalgie Therapeutics, a Marseille-based biotech startup specializing in non-opioid pain treatments. With over 25 years of experience in asset management and corporate finance, Schettini has been instrumental in advancing SMEs with high technological value. His leadership in Tafalgie Therapeutics aims to revolutionize pain treatment by developing novel therapies that tackle acute and chronic pain without the adverse effects associated with conventional painkillers.
Recent Developments
In recent years, Eric Schettini and Tafalgie Therapeutics have made several key advancements:
- September 2025: Tafalgie Therapeutics secured €12 million in a Series A funding round, bringing the total raised since its founding to €30 million. This funding will advance TT5, the company's leading drug candidate, through Phase 2A clinical trials, and further develop other candidates from its research platform. The funding round attracted new business angels and returning investors, including Bpifrance and the EIC. Source
- July 2025: Tafalgie announced promising dose escalation data from its TAFAFIRST Phase 1 study, which involves TT5, a non-opioid treatment for pain. The initial study in Australia is assessing safety, tolerability, and early signals of analgesic efficacy, with completion of Phase 2 expected by 2027. Source
- March 2025: Tafalgie Therapeutics was recognized by the European Innovation Council for developing breakthrough non-opioid molecules for pain treatment. This recognition underscores the increasing European interest in innovative analgesics. Source
- February 2024: The company entered Phase 1 clinical trials in Australia, focusing on TT5, with initial results expected by late 2025. Source
- November 2024: Tafalgie was shortlisted for the Regional EY Entrepreneur of the Year 2024 award, highlighting its innovative approaches to addressing societal health challenges. Source
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Eric Schettini |
| Born | 1964, France |
| Nationality | French |
| Occupation | Entrepreneur, Investor, CEO of Tafalgie Therapeutics |
| Known For | Founder of Tafalgie Therapeutics |
| Net Worth | Not publicly disclosed |
| Education | DEA in Economics Mathematics and Econometrics, Business Law |
Early Life and Education
Eric Schettini was born in France in 1964. He pursued higher education with a focus on economics and law, earning postgraduate degrees from Aix-Marseille Université and Université de Montpellier. His academic background laid the foundation for his career in finance and entrepreneurship. Schettini's formative years were marked by a keen interest in innovative financial solutions and investments, which later saw him excel in asset management and venture capital.
Career and Notable Achievements
Eric Schettini's career is characterized by his leadership in the corporate finance and biopharmaceutical sectors:
- 2000: Founded Viveris Management, managing over €3 billion in assets, focusing on real estate, energy, and private equity.
- 2010: Successfully sold Viveris Management to Swiss Life and ACG Group, transitioning to equity investments via Mirabel Partners.
- 2020: Co-founded Tafalgie Therapeutics, focusing on non-opioid pain treatments, leveraging the TAFA4 protein's therapeutic potential.
- Recognition: Under Schettini's leadership, Tafalgie Therapeutics has been recognized by the European Innovation Council and shortlisted for significant entrepreneurship awards.
Current Work and Impact
Eric Schettini continues to lead Tafalgie Therapeutics in developing innovative pain treatments. The company is advancing a new class of non-opioid drugs aimed at mitigating the global opioid crisis by offering safer alternatives. Tafalgie's research and development efforts are poised to transform chronic pain management, with plans to establish a "Discovery Platform." Schettini's work not only promises advancements in medical treatment but also highlights the importance of strategic investment in biotech innovation.
Conclusion
Eric Schettini's leadership in the biopharmaceutical industry exemplifies his commitment to innovation and addressing unmet medical needs. As the founder of Tafalgie Therapeutics, Schettini is at the forefront of developing non-opioid analgesics, with the potential to impact global pain management protocols significantly. With continued advancements under his leadership, Tafalgie is poised to shape the future of pain treatment, contributing to both public health and biotechnological advancements.